Ligand to Report First Quarter Financial Results on May 4
April 20, 2022EMERYVILLE, Calif.–(BUSINESS WIRE)–#earnings—Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report first quarter 2022 financial results after the close of the U.S. financial markets on Wednesday, May 4, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg.
Conference Call and Webcast Information
|
What: |
Ligand conference call to discuss financial results and provide general business updates |
|
|
Date: |
Wednesday, May 4, 2022 |
|
|
Time: |
4:30 p.m. Eastern time (1:30 p.m. Pacific time) |
|
|
Conference Call: |
Dial (866) 518-6930 within the U.S. |
|
|
Dial (203) 518-9797 outside the U.S. |
||
|
Conference ID is LP1Q22 |
||
|
Webcast: |
Live and replay webcast of the call are available here. |
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) ultimately to generate our revenue. Ligand’s OmniAb® technology platform is a patent-protected transgenic animal platform used in the discovery of fully human monoclonal and bispecific therapeutic antibodies. The Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand’s Pelican Expression Technology® is a robust, validated, cost-effective and scalable platform for recombinant protein production that is especially well-suited for complex, large-scale protein production where traditional systems are not. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Sanofi, Janssen, Takeda, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com.
Follow Ligand on Twitter @Ligand_LGND.
We use Twitter and our investor relations website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our Twitter account and our website, in addition to following our press releases, SEC filings, public conference calls and webcasts.
Contacts
Ligand Pharmaceuticals Incorporated
Simon Latimer
[email protected]
(858) 550-7766
Twitter: @Ligand_LGND
LHA Investor Relations
Bruce Voss
[email protected]
(310) 691-7100